Would you have guessed that the drug production sector produces 50% more metric tons of carbon dioxide per year than the automotive industry?1
Yet, when it comes to this significant contribution to global carbon emissions, the pharmaceutical sector has experienced very little scrutiny.2 When it comes to efforts to slow climate change, no industry should be exempt.
There must be a global effort across the board to reduce cardon dioxide (CO2) emissions; and, with a sizable carbon footprint, the pharmaceutical industry is in a unique position to chip in.
But it doesn't have to be an either/or choice between sustainability and productivity, drug manufacturing can be tailored to be more environmentally friendly without reducing production volume or quality.
Contract development and manufacturing organisations (CDMOs) at the forefront of efforts to improve drug production are poised to implement environmentally friendly practices at scale, thereby serving as a beacon for the rest of the pharma industry to follow.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.